The recent case report published in the JCC on using combined infliximab and surgery in treatment of pyoderma gangrenosum with ulcerative colitis is interesting. 1 Andrisani et al. proposed for the effectiveness of this regimen. 1 The possibility of adverse events on the other side on using infliximab should also be mentioned. The practitioner has to weigh between the usefulness and possible adverse side effect in each individual case. 2 A recent report on the possible relation between using infliximab and Guillain-Barre and Miller Fisher syndromes in a case with ulcerative colitis should be mentioned. 3 The close monitoring for development of immune related symptoms in any immunological disorder cases with monoclonal antibodies including infliximab should be done.
